Telabee Tablet

Telabee Tablet 25 mg

Telabee Tablet 25 mg (TAF) is an antiviral medication used in the treatment of HIV-1 infection. It is a prodrug of tenofovir, and works by interfering with the ability of the virus to copy itself. As a result, it can decrease the amount of HIV in the body. TAF has been approved for use in combination with other antiretroviral agents in patients with HIV-1.

Uses for Telabee Tablet 25 mg

TDF is used in combination with other anti-HIV drugs to treat HIV-1 infection in adults over 18 years of age. It is not recommended for use in patients under 18 years of age.

Brand Name	Telabee
Type	Tablet
Weight	25 mg
Generic	Tenofovir Alafenamide
Manufacturer	Jenphar Bangladesh Ltd.
Available in	English বাংলা

Mechanism of Action

By inhibiting the enzyme reverse transcriptase, tenofovir alafenamide interferes with HIV's ability to replicate itself. This action reduces the amount of virus in the body, allowing the immune system to fight off infection.

How Long Does It Take to Work?

TDF can start working within a few days of taking the drug. However, it can take several weeks for the drug to reach its full effect. Most people will see improvement in their HIV symptoms within a few weeks of starting treatment.

Absorption

TAF is rapidly and complete absorbed in the small intestine when taken by mouth.

Route of Elimination

TAF is primarily eliminated through the kidneys. The majority of the drug is eliminated unchanged in the urine.

Dosage

Testing Prior to Initiation of Tenofovir alafenamide: Prior to initiation of Tenofovir alafenamide, patients should be tested for HIV-1 infection. Tenofovir alafenamide alone should not be used in patients with HIV-1 infection.

Recommended Dosage in Adults: The recommended dosage of Tenofovir alafenamide is 25 mg (one tablet) taken orally once daily with food.

Dosage in Patients with Renal Impairment: No dosage adjustment of Tenofovir alafenamide is required in patients with estimated creatinine clearance greater than or equal to 15 ml per minute or in patients with end stage renal disease (ESRD; estimated creatinine clearance below 15 ml per minute) who are receiving chronic hemodialysis. On days of hemodialysis administer Tenofovir alafenamide after completion of hemodialysis treatment. Tenofovir alafenamide is not recommended in patients with ESRD who are not receiving chronic hemodialysis.

Dosage in Patients with Hepatic Impairment: No dosage adjustment of Tenofovir alafenamide is required in patients with mild hepatic impairment (Child-Pugh A). Tenofovir alafenamide is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.

Pediatric Use: Safety and effectiveness of Tenofovir alafenamide in pediatric patients less than 18 years of age have not been established.

Geriatric Use: In clinical trials, Tenofovir alafenamide was administered to 89 subjects aged 65 and over. No clinically significant differences in safety or efficacy have been observed between elderly subjects and subjects between 18 and less than 65 years of age.

TAF is usually taken once-daily with or without food. The recommended dose is 300 mg taken by mouth.

Administration

TAF is usually taken once-daily with or without food. The recommended dose is 300 mg taken by mouth.

Side Effect

Common side effects of TAF include headaches, nausea, abdominal pain, and diarrhea. Less common side effects include rash, itching, vomiting, and dizziness.

Toxicity

In animal studies, TAF has shown to be safe at doses up to 30 times higher than the recommended dose for humans. The most commonly seen side effects in humans are headache, nausea, and abdominal pain. At high doses (up to 900 mg daily), TAF has been associated with kidney toxicity, though this is rare in humans.

Precaution

TAF should be used with caution in patients with kidney impairment, as it may cause further kidney damage. Patients with liver dysfunction should also be monitored carefully, as TAF may increase the risk of liver damage. It should not be used in pregnant women due to the risk of harm to the fetus.

Interaction

TAF can interact with other medications, such as antacids, anticonvulsants, and corticosteroids. It should not be taken with other drugs that can cause kidney toxicity.

Disease Interaction

TAF works by interfering with the ability of the virus to copy itself, which can decrease the amount of HIV in the body. As a result, TAF can potentially interact with other diseases, and should be used with caution in patients with kidney or liver impairment.

Drug Interaction

TAF can potentially interact with other drugs, such as antacids, anticonvulsants, corticosteroids, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and antibiotics. Patients taking these drugs should be monitored carefully for potential interactions.

Food Interactions

TAF should not be taken with food. Taking it with food can significantly reduce the amount of drug that is absorbed by the body.

Pregnancy Use

TAF is not recommended for use in pregnant women, as it may cause harm to the unborn child. Women who are pregnant should discuss other treatment options with their doctor.

Lactation Use

It is not known if TAF is excreted in breast milk. Women taking TAF should avoid breast-feeding, as it may cause harm to the baby.

Acute Overdose

Symptoms of an overdose include nausea, vomiting, dizziness, and abdominal pain. If an overdose is suspected, medical attention should be sought immediately.

Contraindication

TAF should not be used in patients with severe kidney impairment. It should also be used with caution in patients with liver dysfunction. Pregnant women should not take TAF, as it may cause harm to the fetus.